SAN DIEGO, April 7, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN).
On April 6, 2021, FibroGen issued a statement that reversed on some of the key safety data used to progress hope for their anemia drug roxadustat. Following this news, the price of FibroGen common shares fell over 30% in pre market trading on April 7, 2021.
If you have information that could assist in this investigation, including past employees and others, or if you are a FibroGen shareholder and are interested in learning more about the investigation, please contact Jim Baker ([email protected]) by email or phone at 619-814-4471. If emailing, please include a phone number.
Additionally, you can [click here to join this action]. There is no cost or obligation to you.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
SOURCE Johnson Fistel, LLP